Drugs / LHP588
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06847321 | Feb 2025 → Jan 2029 expected | Alzheimer disease | Lighthouse Pharmaceuticals, Inc. | Recruiting | No outcome recorded |
Press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-11-26 | Lighthouse Pharmaceuticals, Inc. | Lighthouse Pharmaceuticals to Present Phase 2 SPRING Trial of LHP588, a Next-Generation Gingipain Inhibitor for the Treatment of lighthousepharma.com ↗ |
| 2025-08-22 | Lighthouse Pharmaceuticals, Inc. | Lighthouse Pharmaceuticals Receives $49.2 Million Grant from NIA to Advance Phase 2 Study of LHP588 for P. gingivalis-positive Alzheimer's Disease lighthousepharma.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LHP588 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06847321 ↗ |
| Route | Oral | “LHP588 25 mg, LHP588 50 mg, or placebo, orally, once daily (QD) in a fasted state” NCT06847321 ↗ |